Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow RLMD by emailGet an email when RLMD pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about RLMD, unsubscribe in one click. Privacy
📣 What RLMD Says Is Next
by year-end 2026 · “The Company expects to submit an IND by year-end 2026 and initiate the Phase 2 study in Prader-Willi syndrome upon IND clearance.”
Company press release, Aug 6, 2026 · SEC filing
by year-end 2026 · “The Company expects to submit an IND by year-end 2026 and initiate the Phase 3 RESCUE program upon IND clearance. 3 About NMIBC NMIBC represents 75-80% of all bladder cancer cases and is associated with high recurrence rates (50 – 80% over 5 years) and disease progression in a subset of these patients.”
Company press release, Aug 6, 2026 · SEC filing
by year-end 2026 · “This is the remaining step ahead of the sepranolone IND submission, which is expected by year-end 2026.”
Company press release, Aug 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full RLMD picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RLMD and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.